Interview 30 May 2018 How to Close a €3.9B Acquisition Deal for Your Biotech Company Ablynx, one of the big giants in the European biotech arena, closed the final stages of its €3.9B acquisition deal with Sanofi earlier this month, after details were announced in January. Edwin Moses, CEO of Ablynx, shared the company’s success story with attendees at our recent Refresh Meetup in Brussels. The technology behind Ablynx’s success […] May 30, 2018 - 7 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 30 May 2018 Biotech in Germany Celebrates the Closing of a €300M Fund High-Tech Gründerfonds (HTGF), a VC with a long track of biotech investments in Germany, has closed a new fund could benefit the country’s biotech scene. High-Tech Gründerfonds is a German VC that provides seed funding to high-tech startups, including several in the biotech space. The firm has now announced the final closing of a third […] May 30, 2018 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2018 This Immunotherapy Could Be The First to Treat Milk Allergy in Children DBV Technologies has shown in a Phase II trial that its skin patch could desensitize over 60% of children with strong milk allergy. DBV Technologies, one of the largest public biotechs in France, is developing a skin patch technology to treat several forms of food allergies. The company has released new, promising data on its milk […] May 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 May 2018 Positive House Dust Mite Immunotherapy Results for UK Biotech British biotech Allergy Therapeutics reports positive early-stage results for its house dust mite immunotherapy. It’s been a good month for Allergy Therapeutics, which also reported positive Phase II results for its grass pollen allergy vaccine trial last week. It seems to be doing well, with a number of products targeting common allergies in late stage […] May 29, 2018 - 1 minutemin - By Helen Albert Share WhatsApp Twitter Linkedin Email
In Depth 29 May 2018 Clinical Trials in Alzheimer’s Disease Are Failing: What Can Be Done? With no drugs that can stop the progression of the disease and hundreds of clinical trials failing, new fields of research bring hope to people with Alzheimer’s. As the Western population ages, Alzheimer’s disease is becoming one of the biggest diseases of the 21st century. But despite the efforts of science, the FDA and EMA […] May 29, 2018 - 6 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 28 May 2018 Genmab and Janssen Suffer Combination Therapy Setback Janssen will discontinue a Phase I study testing Danish biotech Genmab’s blood cancer blockbuster daratumumab combined with a candidate checkpoint inhibitor in patients with multiple myeloma. Janssen, which obtained the exclusive global rights to commercialize daratumumab from Genmab in 2012, will also discontinue a Phase Ib/II study of daratumumab in patients with non-small cell lung […] May 28, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Best in Biotech 28 May 2018 Top Medical Devices Bringing Innovation to Europe in 2018 When medicine and technology combine, great things can happen. Here are some of the most exciting inventions developed by top medical device companies in Europe. Medicine has come a long way since the era of bloodletting and trepanation. As technology fills our world with computers and automation, many of these advancements are starting to be […] May 28, 2018 - 9 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 25 May 2018 Norwegian Pancreatic Cancer Vaccine Drastically Improves Survival Targovax has obtained positive Phase I/II results showing its pancreatic cancer vaccine improved the survival of 32 patients also receiving chemotherapy over two years. Targovax, based in Oslo, Norway, has obtained positive Phase I/II results confirming the efficacy of its pancreatic cancer vaccine in a larger patient population and over a longer time period than […] May 25, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
Interview 24 May 2018 Sugar-Munching Microbes Put the ‘Eco’ into the Dyeing Industry The commercial dyeing industry is not known for being eco-friendly, which is something that PILI – a synbio startup based in France – is hoping to address with their color producing microbes. Philip chatted with its CEO, Jeremie Blache, to find out more about the company, its recent successful fundraising round and how its technology […] May 24, 2018 - 5 minutesmins - By Helen Albert Share WhatsApp Twitter Linkedin Email
News and Trends 24 May 2018 Organs-on-a-Chip for Drug Research in a Range of Diseases Make it to the Market CN Bio Innovations has globally launched an organ-on-a-chip device that allows scientists to test potential drugs on living human organ models. CN Bio Innovations, an Oxford University spin-out, has launched a device that enables scientists to test potential drugs in conventional cell culture labs without the need for animal models. The technology, which has been […] May 24, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
More News! 23 May 2018 Danish Biotech Raises Series A Round to Advance Microbe Engineering Technology Biosyntia has raised €4M in Series A financing from Sofinnova Partners to bring its microbe engineering technology closer to commercialization. Biosyntia, based in Copenhagen, has raised €4M in Series A financing to continue developing its biosynthetic selection technology to produce complex compounds by fermentation. The funding was provided by Sofinnova Partners, a new investor and leading European […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 23 May 2018 Another Pneumonia Antibiotic is Close to Treating Patients Nabriva Therapeutics has obtained positive Phase III results for its antibiotic lefamulin and plans to seek FDA approval for the drug by the end of this year. Nabriva Therapeutics has obtained a second round of positive Phase III results for lefamulin, its antibiotic targeting community-acquired pneumonia. The drug was shown to be as effective as […] May 23, 2018 - 2 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email